| Literature DB >> 27618027 |
Weifeng Yao1,2, Hui Li3,4, Qinan Liu5,6, Ye Gao7, Jin Dai8, Beihua Bao9,10, Li Zhang11,12, Anwei Ding13,14.
Abstract
Amentoflavone is one of the important bioactive flavonoids in the ethylacetate extract of "Cebaiye", which is a blood cooling and hematostatic herb in traditional Chinese medicine. The previous work in our group has demonstrated that the ethylacetate extract of Cebaiye has a notable antagonistic effect on the injury induced by lipopolysaccharide (LPS) to human umbilical vein endothelial cells (HUVECs). The present investigation was designed to assess the effects and possible mechanism of cytoprotection of amentoflavone via metabolomics. Ultra-performance liquid chromatography/quadrupole time of flight-mass spectrometry (UPLC/QTOF-MS) coupled with multivariate data analysis was used to characterize the variations in the metabolites of HUVECs in response to exposure to LPS and amentoflavone treatment. Seven putative metabolites (glycine, argininosuccinic acid, putrescine, ornithine, spermidine, 5-oxoproline and dihydrouracil) were discovered in cells incubated with LPS and/or amentoflavone. Functional pathway analysis uncovered that the changes of these metabolites related to various significant metabolic pathways (glutathione metabolism, arginine and proline metabolism, β-alanine metabolism and glycine, serine and threonine metabolism), which may explain the potential cytoprotection function of amentoflavone. These findings also demonstrate that cellular metabolomics through UPLC/QTOF-MS is a powerful tool for detecting variations in a range of intracellular compounds upon toxin and/or drug exposure.Entities:
Keywords: amentoflavone; cellular metabolomics; cytoprotection; human umbilical vein endothelial cells; lipopolysaccharide
Mesh:
Substances:
Year: 2016 PMID: 27618027 PMCID: PMC5037791 DOI: 10.3390/ijms17091514
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1The structure of amentoflavone.
The protection of amentoflavone on injury of HUVECs induced by LPS (n = 5, ± s).
| Group | Concentration/μM | NO/μmol·L−1 | MDA/nmol·mL−1 | SOD/U·mL−1 |
|---|---|---|---|---|
| Vehicle control | – | 21.03 ± 0.86 | 1.71 ± 0.13 | 21.69 ± 2.16 |
| Model | – | 53.66 ± 3.07 * | 2.80 ± 0.26 * | 11.11 ± 1.20 * |
| Treatment | 4.647 | 31.62 ± 3.01 # | 2.13 ± 0.13 # | 18.12 ± 0.50 # |
| 9.294 | 27.33 ± 1.79 # | 1.93 ± 0.09 # | 19.26 ± 0.62 # | |
| 18.587 | 22.13 ± 2.28 # | 1.68 ± 0.17 # | 22.21 ± 1.67 # |
represents the mean value and s represents the standard deviation; compared with vehicle control group, * p < 0.01; compared with model group, # p < 0.01
Figure 2The score plots of principal component analysis (PCA): (A) positive, R2X = 0.618, Q2 = 0.396; and (B) negative, R2X = 0.749, Q2 = 0.248. Blue diamond: vehicle control group; Red triangle: model group; Green box: treatment group; Black dot: QC samples.
Figure 3The score plot (t1/t2) of PLS-DA before (A,B) and after (C,D) ANOVA: (A) positive, R2X = 0.375, R2Y = 0.936, Q2Y = 0.579; (B) negative, R2X = 0.431, R2Y = 0.908, Q2Y = 0.617; (C) positive, R2X = 0.684, R2Y = 0.991, Q2Y = 0.843; and (D) negative, R2X = 0.569, R2Y = 0.831, Q2Y = 0.735. Blue diamond: vehicle control group; Red triangle: model group; Green box: treatment group.
The comparison of PLS-DA results.
| Methods | Mode | Features | PLS-DA | ||||
|---|---|---|---|---|---|---|---|
| A a | R2 | R2 | Q2 | Difference b | |||
| MZmine 2.10 | Positive | 1342 | 3 | 0.375 | 0.936 | 0.579 | 0.357 |
| Negative | 241 | 3 | 0.431 | 0.908 | 0.617 | 0.291 | |
| ANOVA ( | Positive | 307 | 5 | 0.684 | 0.991 | 0.843 | 0.148 |
| Negative | 31 | 2 | 0.569 | 0.831 | 0.735 | 0.096 | |
a The number of latent variables; b The difference between R2Y and Q2Y; c The data from MZmine are processed by ANOVA before PLS-DA.
Potential biomarkers and their cellular positions.
| Mode | No. | R.T. (min) a | Mass ( | Adduct Ion | Delta | Formula | Compound | Trend b | Trend c | Cellular Location d |
|---|---|---|---|---|---|---|---|---|---|---|
| Positive | 1 | 0.343 | 113.9899 | M + K | 0.0053 | C2H5NO2 | Glycine | ↓ | ↑ | Mitochondria |
| 2 | 0.738 | 308.1522 | M + NH4 | 0.0043 | C10H18N4O6 | Argininosuccinic acid | ↓ | ↑ | Cytoplasm | |
| 3 | 4.988 | 127.0632 | M + K | 0.0000 | C4H12N2 | Putrescine | ↓ | ↑ | Mitochondria | |
| 4 | 13.744 | 133.0936 | M + H | 0.0035 | C5H12N2O2 | Ornithine | ↓ | ↑ | Mitochondria | |
| 5 | 14.671 | 163.1976 | M + NH4 | 0.0058 | C7H19N3 | Spermidine | ↓ | ↑ | Cytoplasm | |
| Negative | 1 | 0.733 | 128.0383 | M − H | 0.0030 | C5H7NO3 | 5-oxoproline | ↓ | ↑ | Cytoplasm |
| 2 | 14.850 | 113.0293 | M − H | 0.0063 | C4H6N2O2 | Dihydrouracil | ↑ | ↓ | Cytoplasm |
a R.T.: retention time of the components; b ↑ and ↓ represent up- and down-regulation of the metabolites in model group compared with the vehicle control group, respectively; c ↑ and ↓ represent the significant up- and down-regulation of the metabolites in amentoflavone treatment group compared with the model group, respectively; d The cellular position of metabolites from Human Metabolome Database (HMDB).
Figure 4Overview of pathway analysis from pathway topology analysis. A: β-Alanine metabolism; B: glutathione metabolism; C: glycine, serine and threonine metabolism; and D: arginine and proline metabolism.
Figure 5Correlation networks of all the potential biomarkers in LPS stressed and amentoflavone treated cells. Metabolites in yellow boxes represent altered biomarkers determined by UPLC/QTOF-MS. The green boxes represent the pathway including the metabolites around.